Policy | February 22, 2023
Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Subscribe To Our Newsletter & Stay Updated
